½ÃÀ庸°í¼­
»óǰÄÚµå
1636769

¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå ¿¹Ãø(-2030³â) : °Ë»ç À¯Çüº°, ±â¼úº°, À¯Åë ä³Îº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®

Consumer Genomics Market Forecasts to 2030 - Global Analysis By Test Type (Health Risk Testing, Traits Testing, Carrier Screening and Pharmacogenomics), Technology, Distribution Channel, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é, ¼¼°è ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀåÀº 2024³â 19¾ï 7,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È 26.8%ÀÇ CAGR·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 82¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ÒºñÀÚ À¯ÀüüÇÐÀº °³Àο¡°Ô Á÷Á¢ À¯ÀüÀÚ °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇÏ´Â À¯ÀüüÇÐÀÇ ÇÑ ºÐ¾ß·Î, DNA¸¦ °Ë»çÇÏ¿© Á¶»ó, °Ç°­, À£ºù ¹× °³ÀÎÀû Ư¼º¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¼ÒºñÀÚ´Â ¶óÀÌÇÁ½ºÅ¸ÀÏ ¼±ÅÃÀ» ÃÖÀûÈ­Çϰí, °Ç°­ °ü¸®¸¦ ¸ÂÃãÈ­Çϰí, Áúº´¿¡ ´ëÇÑ À¯ÀüÀû ¼ÒÀÎÀ» ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ À¯ÀüüÇÐÀº Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®°ú À¯ÀüÇüÁú ºÐ¼®°ú °°Àº ÷´Ü ±â¼úÀ» Ȱ¿ëÇÏ¿© À¯ÀüÀÚ Á¤º¸¸¦ ½±°Ô Á¢±ÙÇϰí ÇÕ¸®ÀûÀÎ °¡°ÝÀ¸·Î Á¦°øÇÕ´Ï´Ù. ´ÙÀÌ·ºÆ® Åõ ÄÁ½´¸Ó Ç÷§ÆûÀº °³ÀÎ °Ç°­ °ü¸®¸¦ º¯È­½Ã۰í À¯ÀüÀû ¿µÇâ¿¡ ´ëÇÑ Áö½ÄÀ» Çâ»ó½ÃÅ´À¸·Î½á ÀÌ »ê¾÷ÀÇ Àαâ È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

±¹Á¦¾Ï¿¬±¸¼Ò(IARC)¿¡ µû¸£¸é, 2040³â±îÁö ¹ÌÁø´Ü ¾Ï ȯÀÚ ¼ö´Â 3,020¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»óÀ̳ª À¯ÀüÀû À¯»ê¿¡ ´ëÇÑ °ü½É Áõ°¡

À¯ÀüÀû À¯»ê°ú Á¶»ó¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¼ÒºñÀÚ À¯ÀüüÇÐ ºÐ¾ß¿¡ Å« ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, DNA °Ë»ç ŰƮ´Â »ç¶÷µéÀÌ ÀÚ½ÅÀÇ Á¶»ó°ú ¹ÎÁ·Àû ¹è°æ¿¡ ´ëÇØ ´õ ¸¹ÀÌ ¾Ë°íÀÚ ÇÏ´Â ¿å±¸°¡ Ä¿Áö¸é¼­ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ë´ëÀûÀÎ ¸¶ÄÉÆÃ°ú ¼ÒºñÀÚ Á÷Á¢ °Ë»ç ¼­ºñ½ºÀÇ °¡¿ë¼º µî ¿©·¯ °¡Áö º¯¼ö°¡ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¸¹Àº ¼ÒºñÀÚµéÀÌ ÀÚ½ÅÀÇ Á¶»ó¿¡ ´ëÇØ ´õ ¸¹ÀÌ ¾Ë°í ½Í°í, Á¶»ó°ú ¿¬°áµÇ±â¸¦ ¿øÇϰí, 23andMe¿Í Ancestry¿Í °°Àº ±â¾÷µéÀº Á¶»ó ¿¬±¸¿Í °³ÀÎÀû ¹ß°ßÀ» À§ÇÑ À¯ÀüÀÚ °Ë»çÀÇ ¸Å·ÂÀ» ³ôÀÌ´Â ±¤¹üÀ§ÇÑ µ¥ÀÌÅͺ£À̽º¸¦ ±¸ÃàÇÔÀ¸·Î½á ÀÌ·¯ÇÑ °ü½ÉÀ¸·ÎºÎÅÍ ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù. ÀÌ °ü½ÉÀ¸·ÎºÎÅÍ ÀÌÀÍÀ» ¾ò°í ÀÖ½À´Ï´Ù.

±â¼ú°ú µ¥ÀÌÅÍ ÅëÇÕÀÇ °úÁ¦

°Ë»ç ÀýÂ÷ÀÇ Ç¥ÁØÈ­ ºÎÁ·Àº ¿©·¯ »ç¾÷ÀÚ °£¿¡ Àϰü¼º ¾ø´Â °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ´Â ½É°¢ÇÑ ¹®Á¦ÀÔ´Ï´Ù. ¶ÇÇÑ, ±ÔÁ¦ °¨µ¶ÀÇ ºÎÀç´Â À¯ÀüÀÚ µ¥ÀÌÅÍ ÇØ¼®ÀÇ ½Å·Ú¼º°ú Á¤È®¼º¿¡ ÀDZ¸½ÉÀ» ºÒ·¯ÀÏÀ¸Å°°í °í°´ÀÇ ½Å·Ú¸¦ ¶³¾î¶ß¸± ¼ö ÀÖ½À´Ï´Ù. Áß¿äÇÑ ¹®Á¦·Î´Â µ¥ÀÌÅÍ ¾ÈÀü°ú ÇÁ¶óÀ̹ö½Ã°¡ ÀÖ½À´Ï´Ù. »ç¶÷µéÀº ³²¿ë ¹× ¹«´Ü ¾×¼¼½º¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÀÚ½ÅÀÇ À¯ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý, ÀúÀå ¹× »ç¿ë¿¡ ´ëÇÑ ¿ì·Á°¡ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇÏ´Â °ÍÀº ½Å·Ú¸¦ ±¸ÃàÇÏ°í ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀåÀ» º¸ÀåÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÇコÄÉ¾î ¹× À£´Ï½º ¼­ºñ½º È®´ë

À¯ÀüüÇÐÀÇ ¹ß´Þ·Î »ç¶÷µéÀº ´Ù¾çÇÑ Áúº´¿¡ ´ëÇÑ À¯ÀüÀû °¨¼ö¼º¿¡ ´ëÇÑ Á¤º¸¿¡ Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾î Áúº´À» Á¶±â¿¡ ¹ß°ßÇϰí Àû±ØÀûÀ¸·Î °Ç°­À» °ü¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. Á¾ÇÕÀûÀÎ °Ç°­ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ´Ù¾çÇÑ À£´Ï½º ±â¾÷µéÀº À¯ÀüÀÚ µ¥ÀÌÅ͸¦ Ȱ¿ëÇØ °³Àο¡°Ô ¸Â´Â ÇÇÆ®´Ï½º, ½Äǰ, ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» Á¦¾ÈÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ä¡·á È¿°ú¸¦ ±Ø´ëÈ­ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ À¯ÀüÀÚ Á¤º¸¸¦ Ȱ¿ëÇÑ ¸ÂÃ㠾๰ Ä¡·áÀÎ ÆÄ¸¶ÄÚÀ¯Àüü¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ´õ ¸¹Àº À£´Ï½º ÇÁ·Î±×·¥°ú ÇコÄɾî Àü¹®°¡µéÀÌ À¯ÀüÇÐÀ» Ȱ¿ëÇÏ°í °³ÀÎÈ­µÈ °Ç°­ ¼Ö·ç¼ÇÀÇ È¿°ú¿Í Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

°³ÀÎ Á¤º¸ º¸È£ ¹× µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ¿ì·Á

¼ÒºñÀÚµéÀº µ¥ÀÌÅÍ À¯Ãâ, ¹«´Ü Á¢±Ù ¹× ¾Ç¿ëÀÇ À§Çè ¶§¹®¿¡ ±â¾÷¿¡ DNA Á¤º¸¸¦ Á¦°øÇÏ´Â °ÍÀ» ÁÖÀúÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¿Â¶óÀÎ À¯ÀüÀÚ °Ë»ç Ç÷§ÆûÀÇ ÀαⰡ ³ô¾ÆÁü¿¡ µû¶ó À¯ÀüÀÚ µ¥ÀÌÅÍÀÇ ÀúÀå ¹× ±³È¯Àº °³ÀÎ µ¥ÀÌÅÍ º¸¾È¿¡ ´ëÇÑ ½É°¢ÇÑ ¿ì·Á¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ì·Á´Â º¸ÇèÀ̳ª Á÷ÀåÀ» Æ÷ÇÔÇÑ Â÷º°Àû ¸ñÀûÀ¸·Î À¯ÀüÀÚ Á¤º¸°¡ »ç¿ëµÉ °¡´É¼º¿¡ ÀÇÇØ ´õ¿í Ä¿Áý´Ï´Ù. µû¶ó¼­ °í°´ÀÇ ½Å·Ú¸¦ ¾ò°í ½ÃÀå È®´ë¸¦ º¸ÀåÇϱâ À§Çؼ­´Â °­·ÂÇÑ µ¥ÀÌÅÍ º¸È£ Á¤Ã¥, Åõ¸íÇÑ µ¿ÀÇ ÀýÂ÷ ¹× ±ÔÁ¦ Áؼö°¡ ÇʼöÀûÀÔ´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

COVID-19 ÆÒµ¥¹ÍÀº ¼ÒºñÀÚ À¯Àüü ½ÃÀå¿¡ ´Ù¾çÇÑ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ÇÑÆíÀ¸·Î, ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ °³ÀÎ °Ç°­, À£ºù, À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁ³°í, ¼ÒºñÀÚµéÀº COVID-19¸¦ Æ÷ÇÔÇÑ Áúº´¿¡ ´ëÇÑ À¯ÀüÀû À§ÇèÀ» ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀ» ¸ð»öÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÇÑÆí, ¹°·ù ¹®Á¦, °Ë»ç ó¸® Áö¿¬, °ø±Þ¸Á È¥¶õÀÌ ÀϽÃÀûÀ¸·Î ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª °¡Á¤ ³» °Ç°­°ËÁø¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µðÁöÅÐ ÇコÄɾî·ÎÀÇ ÀüȯÀº ¼ÒºñÀÚ À¯Àüü ½ÃÀåÀÇ Àå±âÀûÀÎ ¼ºÀå¿¡ ±â¿©Çß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È À¯ÀüüÇÐ ºÐ¾ß°¡ °¡Àå Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)ÀÇ µîÀåÀ¸·Î À¯ÀüÀÚ °Ë»ç°¡ º¸´Ù ½±°í, Àú·ÅÇϰí, Á¤È®ÇØÁ® º¸±ÞÀÌ ÃËÁøµÊ¿¡ µû¶ó À¯ÀüÇü ºÐ¼® ºÎ¹®ÀÌ °¡Àå Å« ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¼ÒºñÀÚµéÀº ÀÚ½ÅÀÇ °Ç°­À» Àû±ØÀûÀ¸·Î °ü¸®Çϱâ À§ÇØ ¸ÂÃãÇü °Ç°­ ÀλçÀÌÆ®¸¦ Á¡Á¡ ´õ ¸¹ÀÌ ¿ä±¸Çϰí ÀÖÀ¸¸ç, ÀÌ´Â À¯ÀüÀÚ °Ë»ç ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â À¯Àüü µ¥ÀÌÅÍÀÇ ºÐ¼®°ú Àû¿ëÀ» °­È­ÇÏ¿© °³ÀÎÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ¶óÀÌÇÁ½ºÅ¸ÀÏ ¹× °Ç°­ °ü¸® °áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áö¿øÇÏ´Â µðÁöÅÐ °Ç°­ ±â¼úÀÇ ÅëÇÕÀ¸·Î ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»ó

°³ÀÎÈ­ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ¿¹¹æ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°øÀÚ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÇ·á Àü¹®°¡µéÀÌ À¯ÀüÀû ÀλçÀÌÆ®ÀÇ °¡Ä¡¸¦ ÀνÄÇÔ¿¡ µû¶ó Ä¡·á¸¦ Á¶Á¤ÇÏ°í °Ç°­ °á°ú¸¦ °³¼±Çϱâ À§ÇØ È¯ÀÚ Ä¡·á¿¡ À¯Àüü Á¤º¸¸¦ ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÌ °Ç°­¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ À¯ÀüÀÚ °Ë»ç ¼­ºñ½º¸¦ Á¦°øÇϵµ·Ï Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Àüü ±â¼úÀÇ ¹ßÀü°ú ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ ¸¶·ÃµÊ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿Í À¯Àüü °ü·Ã ±â¾÷ °£ÀÇ Çù¾÷ÀÌ ÃËÁøµÇ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª:

¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ ÁöÃâ Áõ°¡, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, Â÷¼¼´ë ¿°±â¼­¿­ ºÐ¼®(NGS)°ú °°Àº À¯Àüü ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ À¯ÀüÀÚ °Ë»ç°¡ ´õ Àú·ÅÇÏ°í ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼­´Â ½º¸¶Æ®Æù°ú ÀÎÅͳÝÀÇ º¸±ÞÀÌ È®´ëµÇ¸é¼­ ¼ÒºñÀÚ Á÷Á¢ °Å·¡(DTC) À¯ÀüÀÚ °Ë»ç ¼­ºñ½ºÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¸ÂÃãÇü ÇコÄɾ ´ëÇÑ ¼ÒºñÀÚ ÀÎ½Ä Áõ°¡, °¡Á¤ ³» À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, À¯Àüü ±â¼úÀÇ ¹ßÀü µî¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á ÀÎÇÁ¶ó°¡ Àß °®Ãß¾îÁ® ÀÖ°í, À¯ÀüÀÚ °Ë»ç ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ôÀ¸¸ç, °¡Ã³ºÐ ¼ÒµæÀÌ ³ô´Ù´Â ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ºÏ¹Ì¿¡¼­´Â À¯ÀüÀÚ ¿¬±¸¿Í µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹ý¿¡ ´ëÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Áö¿øÀÌ °­ÇØ ¼ÒºñÀÚÀÇ Âü¿©¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½º¸¶Æ® ÇコÄɾî¿Í À£´Ï½º Æ®·»µåÀÇ È®»êµµ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹«·á Ä¿½ºÅ͸¶ÀÌ¡ ¼­ºñ½º:

º» º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù:

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤Ä¡, ¿¹Ãø, CAGR(ÁÖ: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç Á¤º¸ Ãâó
    • 1Â÷ Á¶»ç Á¤º¸ Ãâó
    • 2Â÷ Á¶»ç Á¤º¸ Ãâó
    • °¡Á¤

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ±â¼ú ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾»ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯Àüü ½ÃÀå : °Ë»ç À¯Çüº°

  • °Ç°­ ¸®½ºÅ© Å×½ºÆ®
  • Ư¼º Å×½ºÆ®
  • ij¸®¾î ½ºÅ©¸®´×
  • ¾à¹°À¯ÀüüÇÐ

Á¦6Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå : ±â¼úº°

  • Â÷¼¼´ë ½ÃÄö½Ì(NGS)
  • ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR)
  • ¸¶ÀÌÅ©·Î¾î·¹ÀÌ
  • CRISPR ±â¹Ý ±â¼ú
  • ÇÙ»ê ÃßÃâ°ú Á¤Á¦
  • À¯ÀüÀÚÇü ºÐ¼®
  • ±âŸ ±â¼ú

Á¦7Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå : À¯Åë ä³Îº°

  • ¼Ò¸ÅÁ¡
  • ¿Â¶óÀÎ Ç÷§Æû
  • ÇコÄÉ¾î ½Ã¼³

Á¦8Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå : ¿ëµµº°

  • Á¶»ó°ú ¹ÎÁ· °Ë»ç
  • °Ç°­°ú À£´Ï½º
  • ¸ÂÃãÇü ÀÇ·á
  • À¯ÀüÀû °ü·Ã¼º
  • Áø´Ü
  • ¶óÀÌÇÁ½ºÅ¸ÀÏ, °Ç°­, ¿µ¾ç
  • »ý½Ä¿¡ °üÇÑ °Ç°­
  • ½ºÆ÷Ã÷ ¿µ¾ç°ú °Ç°­
  • ±âŸ ¿ëµµ

Á¦9Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • Á¦¾àȸ»ç
  • ÇコÄɾî Á¦°øÀÚ
  • ¿¬±¸±â°ü
  • °³ÀμҺñÀÚ
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦10Àå ¼¼°èÀÇ ¼ÒºñÀÚ À¯ÀüüÇÐ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Çù¾÷, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • Ancestry.com LLC
  • MyHeritage Ltd.
  • Helix OpCo LLC
  • Living DNA Ltd.
  • Veritas Genetics
  • Mapmygenome India Ltd.
  • Pathway Genomics Corporation
  • Color Genomics, Inc.
  • Invitae Corporation
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Fulgent Genetics, Inc.
  • Nebula Genomics
  • Orig3n, Inc.
  • EasyDNA
  • TellmeGen
  • Genetic Technologies Limited
KSM 25.03.04

According to Stratistics MRC, the Global Consumer Genomics Market is accounted for $1.97 billion in 2024 and is expected to reach $8.21 billion by 2030 growing at a CAGR of 26.8% during the forecast period. Consumer genomics refers to the branch of genomics that provides genetic testing services directly to individuals, enabling them to explore their DNA for insights into ancestry, health, wellness, and personal traits. It enables consumers to optimize lifestyle choices, customize healthcare, and comprehend genetic predispositions to diseases. Consumer genomics provides easily available and reasonably priced genetic information by leveraging cutting-edge technology such as next-generation sequencing and genotyping. Direct-to-consumer platforms have helped this industry grow in popularity by transforming personal healthcare and raising knowledge of genetic influences.

According to the International Agency for Research on Cancer (IARC), the number of un-diagnosed cancer cases is expected to reach 30.2 MN, by 2040.

Market Dynamics:

Driver:

Increased interest in ancestry and genetic heritage

Growing interest in genetic heritage and ancestry is having a big impact on the consumer genomics sector. DNA testing kits are in high demand as people try to learn more about their ancestry and ethnic backgrounds. Numerous variables, such as extensive marketing and the availability of direct-to-consumer testing services, are contributing to this trend. A record number of tests are being undertaken because many consumers are driven by a desire to learn more about their ancestry and connect with their ancestors. Businesses such as 23andMe and Ancestry have benefited from this interest by building extensive databases that increase the allure of genetic testing for ancestry research and personal discovery.

Restraint:

Technological and data integration challenges

Lack of standardization in testing procedures is a significant problem that can provide inconsistent outcomes across several businesses. Furthermore, the lack of regulatory supervision casts doubt on the dependability and correctness of interpreting genetic data, which could erode customer confidence. Critical issues include data security and privacy; people are growing more concerned about the collection, storage, and use of their genetic data out of concern about abuse or illegal access. Resolving these issues is crucial to building trust and guaranteeing the market's long-term growth.

Opportunity:

Expansion of healthcare and wellness services

The development of genomics has given people access to information about their genetic susceptibilities to various illnesses, enabling early disease detection and proactive health management. In order to improve overall health results, a variety of wellness companies are using genetic data to provide individualized fitness, food, and lifestyle recommendations. Additionally, pharmacogenomics the customization of pharmaceutical therapies using genetic information is being employed to maximize therapeutic efficacy and minimize side responses. The market for consumer genomics is growing as more wellness programs and healthcare professionals use genetics, increasing the effectiveness and accessibility of personalized health solutions.

Threat:

Privacy and data security concerns

Consumers are frequently hesitant to give businesses their DNA information because of the possible dangers of data breaches, illegal access, and abuse. With the growing popularity of online genetic testing platforms, the storage and exchange of genetic data raises serious concerns regarding the security of personal data. These worries are further heightened by the possibility that genetic information would be utilized for discriminatory purposes, including in insurance or the workplace. Therefore, it is essential to have strong data protection policies, transparent consent procedures, and regulatory compliance in order to gain the trust of customers and guarantee market expansion

Covid-19 Impact

The COVID-19 pandemic had a mixed impact on the consumer genomics market. On one hand, the pandemic led to an increased focus on personal health, wellness, and genetic testing as consumers sought ways to better understand their genetic risks for diseases, including COVID-19. On the other hand, logistical challenges, delays in test processing, and disruptions in supply chains temporarily affected the market. However, the growing demand for at-home health testing and the shift to digital healthcare contributed to the long-term growth of the consumer genomics market.

The genotyping segment is expected to be the largest during the forecast period

The genotyping segment is estimated to be the largest, due to the emergence of next-generation sequencing (NGS) has made genetic testing more accessible, affordable, and accurate, facilitating widespread adoption. Additionally, consumers are increasingly seeking personalized health insights to manage their well-being proactively, leading to a surge in demand for genetic testing services. This trend is further supported by the integration of digital health technologies, which enhance the analysis and application of genomic data, empowering individuals to make informed lifestyle and healthcare decisions.

The healthcare providers segment is expected to have the highest CAGR during the forecast period

The healthcare providers segment is anticipated to witness the highest CAGR during the forecast period, due to the rising emphasis on personalized medicine and the increasing demand for preventive healthcare solutions. As healthcare professionals recognize the value of genetic insights, they are integrating genomic information into patient care to tailor treatments and improve health outcomes. The growing awareness among consumers about the influence of genetics on health is prompting providers to offer genetic testing services. Additionally, advancements in genomic technologies and supportive regulatory frameworks are facilitating collaborations between healthcare providers and genomics companies, further driving market growth.

Region with largest share:

Asia Pacific is expected to have the largest market share during the forecast period due to increasing healthcare expenditure, rising prevalence of chronic diseases, and growing awareness of personalized medicine. Additionally, advancements in genomic technologies, such as next-generation sequencing (NGS), are making genetic testing more affordable and accessible. Furthermore, the increasing adoption of smartphones and internet penetration in the region is facilitating the growth of direct-to-consumer (DTC) genetic testing services.

Region with highest CAGR:

During the forecast period, the North America region is anticipated to register the highest CAGR, owing to rising consumer awareness of personalized healthcare, growing demand for at-home genetic testing, and advancements in genomic technologies. The region benefits from a well-established healthcare infrastructure, with easy access to genetic testing services and a high level of disposable income. Additionally, North America sees strong regulatory support for genetic research and data privacy laws, further encouraging consumer participation. The widespread adoption of smart healthcare and wellness trends also propels market growth in the region.

Key players in the market

Some of the key players profiled in the Consumer Genomics Market include Ancestry.com LLC, MyHeritage Ltd., Helix OpCo LLC, Living DNA Ltd., Veritas Genetics, Mapmygenome India Ltd., Pathway Genomics Corporation, Color Genomics, Inc., Invitae Corporation, Thermo Fisher Scientific Inc., Illumina, Inc., Fulgent Genetics, Inc., Nebula Genomics, Orig3n, Inc., EasyDNA, TellmeGen, and Genetic Technologies Limited.

Key Developments:

In July 2024, Ancestry Launches NEW Interactive DNA Compare Experience to Help Fans Discover How Their DNA Compares to More Than 15 World-Class Athletes.

In December 2023, Helix and Sanford Health Partner on 100K Population Genomics Health Initiative in Upper Midwest. Genomics company Helix and healthcare system Sanford Health announced a population genomics partnership to bring precision medicine to rural communities in the Upper Midwest.

Test Types Covered:

  • Health Risk Testing
  • Traits Testing
  • Carrier Screening
  • Pharmacogenomics

Technologies Covered:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • CRISPR-based Technologies
  • Nucleic Acid Extraction and Purification
  • Genotyping
  • Other Technologies

Distribution Channels Covered:

  • Retail Stores
  • Online Platforms
  • Healthcare Facilities

Applications Covered:

  • Ancestry & Ethnicity Testing
  • Health & Wellness
  • Personalized Medicine
  • Genetic Relatedness
  • Diagnostics
  • Lifestyle, Wellness, and Nutrition
  • Reproductive Health
  • Sports Nutrition and Health
  • Other Applications

End Users Covered:

  • Pharmaceutical Companies
  • Healthcare Providers
  • Research Institutions
  • Individual Consumers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Consumer Genomics Market, By Test Type

  • 5.1 Introduction
  • 5.2 Health Risk Testing
  • 5.3 Traits Testing
  • 5.4 Carrier Screening
  • 5.5 Pharmacogenomics

6 Global Consumer Genomics Market, By Technology

  • 6.1 Introduction
  • 6.2 Next-Generation Sequencing (NGS)
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Microarray
  • 6.5 CRISPR-based Technologies
  • 6.6 Nucleic Acid Extraction and Purification
  • 6.7 Genotyping
  • 6.8 Other Technologies

7 Global Consumer Genomics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Stores
  • 7.3 Online Platforms
  • 7.4 Healthcare Facilities

8 Global Consumer Genomics Market, By Application

  • 8.1 Introduction
  • 8.2 Ancestry & Ethnicity Testing
  • 8.3 Health & Wellness
  • 8.4 Personalized Medicine
  • 8.5 Genetic Relatedness
  • 8.6 Diagnostics
  • 8.7 Lifestyle, Wellness, and Nutrition
  • 8.8 Reproductive Health
  • 8.9 Sports Nutrition and Health
  • 8.10 Other Applications

9 Global Consumer Genomics Market, By End User

  • 9.1 Introduction
  • 9.2 Pharmaceutical Companies
  • 9.3 Healthcare Providers
  • 9.4 Research Institutions
  • 9.5 Individual Consumers
  • 9.6 Other End Users

10 Global Consumer Genomics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Ancestry.com LLC
  • 12.2 MyHeritage Ltd.
  • 12.3 Helix OpCo LLC
  • 12.4 Living DNA Ltd.
  • 12.5 Veritas Genetics
  • 12.6 Mapmygenome India Ltd.
  • 12.7 Pathway Genomics Corporation
  • 12.8 Color Genomics, Inc.
  • 12.9 Invitae Corporation
  • 12.10 Thermo Fisher Scientific Inc.
  • 12.11 Illumina, Inc.
  • 12.12 Fulgent Genetics, Inc.
  • 12.13 Nebula Genomics
  • 12.14 Orig3n, Inc.
  • 12.15 EasyDNA
  • 12.16 TellmeGen
  • 12.17 Genetic Technologies Limited
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦